Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 29 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Imprialos, Konstantinos P [Clear All Filters]
Determinants of pulse wave velocity index and potential implementations..
J Clin Hypertens (Greenwich).
(2019). Insomnia and hypertension: A misty landscape..
J Clin Hypertens (Greenwich). 21(6), 835-837.
(2019).
(2019). Antihypertensive drug treatment: the real-life challenge..
J Clin Hypertens (Greenwich). 20(1), 115-117.
(2018). Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?.
J Clin Hypertens (Greenwich). 20(2), 255-257.
(2018). Diabetes and lipid metabolism..
Hormones (Athens). 17(1), 61-67.
(2018). Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes..
N Engl J Med. 378(10), 967.
(2018). Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?.
J Clin Hypertens (Greenwich). 20(3), 469-471.
(2018). The potential role of statins in treating liver disease..
Expert Rev Gastroenterol Hepatol. 12(4), 331-339.
(2018). Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?.
J Clin Hypertens (Greenwich). 20(5), 942-948.
(2018). Renal resistive index for renovascular hypertension: In the quest of the Holy Grail..
J Clin Hypertens (Greenwich). 20(3), 589-591.
(2018). Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?.
J Clin Hypertens (Greenwich). 20(4), 634-636.
(2018). Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension..
J Clin Hypertens (Greenwich). 20(1), 65-68.
(2018). Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs..
Cardiovasc Hematol Disord Drug Targets. 18(2), 104-113.
(2018). Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease..
Cardiovasc Hematol Disord Drug Targets. 18(2), 120-126.
(2018). Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs..
Cardiovasc Hematol Disord Drug Targets. 18(2), 83-85.
(2018). Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?.
J Hypertens. 36(3), 701.
(2018). Abnormal blood pressure dipping in diabetic kidney disease: A black-race nightmare?.
J Clin Hypertens (Greenwich). 19(12), 1336-1338.
(2017). Blood pressure and cardiovascular outcomes: a closer look..
Lancet. 389(10076), 1295-1296.
(2017). The effect of SGLT2 inhibitors on cardiovascular events and renal function..
Expert Rev Clin Pharmacol. 10(11), 1251-1261.
(2017). Liraglutide and Renal Outcomes in Type 2 Diabetes..
N Engl J Med. 377(22), 2196.
(2017). Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes..
N Engl J Med. 377(25), 2502.
(2017). Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?.
J Neurol Neurosurg Psychiatry. 88(3), 249-253.
(2017). Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look at Additional Parameters..
JAMA Intern Med. 177(9), 1393.
(2017). Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?.
Am J Hypertens. 29(5), 662.
(2016).